FLUCELVAX QUADRIVALENT Important Safety Information READ MORE
It was the first breakthrough in flu vaccine
production technology in over 40 years.1
Scroll down to see how FLUCELVAX QUADRIVALENT can
help reshape the way you think about flu shots.
FLUCELVAX QUADRIVALENT (Influenza Vaccine) is made with advanced cell culture technology in closed bioreactors, eliminating the need for antibiotics.
Don't let the flu slow you down. Help protect yourself from the flu with FLUCELVAX QUADRIVALENT (Influenza Vaccine).
Ready to Use
FLUCELVAX QUADRIVALENT (Influenza Vaccine) comes in pre-filled syringes. It is 100% free of preservatives, antibiotics and latex.
In studies, FLUCELVAX QUADRIVALENT was shown to generate a strong immune response and was well tolerated.2
FLUCELVAX QUADRIVALENT is made using cell culture technology3, which does not rely on eggs for manufacturing and has the potential to rapidly increase production of flu shots in times of need. It is also antibiotic, preservative, and latex free, and it helps protect against 4 strains of the flu in people aged 4 years and older.
Ask your doctor or pharmacist for FLUCELVAX QUADRIVALENT.
Social Flu Tracker
The World's First
Socially Enabled Flu Tracker
The Social Flu Tracker is the world's first socially driven flu tracker using social media to monitor the chatter about the flu virus in real time. The map is tracking hashtags such as #flu #fluseason #fluvirus and others in social conversations in the United States and plotting them on the map according to where the chatter is started.Join the Conversation with a tweet
1. Center for Infectious Disease Research & Policy. The compelling need for game-changing influenza vaccines: an analysis of the influenza vaccine enterprise and recommendations for the future. www.cidrap.umn.edu/cidrap/files/80/ccivi%20report.pdf. Published October 2012. Accessed July 20, 2015.
2. FLUCELVAX QUADRIVALENT [package insert]. Holly Springs, NC. Seqirus, Inc: 2016.
3. FDA approves first seasonal influenza vaccine manufactured using cell culture technology [news release]. Silver Spring, MD: U.S. Food and Drug Administration; November 20, 2012.